Literature DB >> 9630369

Clinical impact and associated costs of Clostridium difficile-associated disease.

R C Spencer1.   

Abstract

Toxin-producing Clostridium difficile is the commonest cause of nosocomial diarrhoea and, as such, poses a major problem in our hospitals. The main population susceptible to disease is the elderly, for reasons that remain unclear. By contrast, carriage rates in neonates are high, but disease is low. The organism also has a major clinical impact in the immunosuppressed host, patients undergoing surgery (especially gastrointestinal) and those with severe underlying disease and longer hospital stay. Other interventions with high-risk associations are enemas, nasogastric and gastrostomy tubes and anti-peristaltic drugs. Data on the associated costs of C. difficile diarrhoea are not freely available, but one estimate is that in an average-sized district general hospital, 100 cases of C. difficile infection can be expected each year with an extra annual cost of 400,000 pound sterling and 2100 lost bed days.

Entities:  

Mesh:

Year:  1998        PMID: 9630369     DOI: 10.1093/jac/41.suppl_3.5

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; A Richard; K Hamadi; V Chomette; B Burghoffer; J C Petit
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Horizontal transfer of erythromycin resistance from Clostridium difficile to Butyrivibrio fibrisolvens.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Community-acquired pneumonia: doctors do not follow national guidelines.

Authors:  Paul Collini; Mike Beadsworth; Jim Anson; Tim Neal; Peter Burnham; Paul Deegan; Nick Beeching; Alastair Miller
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

5.  Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Authors:  K L Kotloff; S S Wasserman; G A Losonsky; W Thomas; R Nichols; R Edelman; M Bridwell; T P Monath
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus.

Authors:  N J Asha; D Tompkins; M H Wilcox
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

7.  Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  D O'Connor; P Hynes; M Cormican; E Collins; G Corbett-Feeney; M Cassidy
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

8.  Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study.

Authors:  N Eliakim-Raz; G Fishman; D Yahav; E Goldberg; G Y Stein; H B Zvi; A Barsheshet; J Bishara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

9.  A novel method for rapidly diagnosing the causes of diarrhoea.

Authors:  C S J Probert; P R H Jones; N M Ratcliffe
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 10.  Hypervirulent strains of Clostridium difficile.

Authors:  Barry Cookson
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.